Synthesis and cyclization of modified prostate-specific antigen activating peptides using solid-phase peptide synthesis method by Ekabe, Joel O
 
 
 
 
 
 
 
 
 
 
SYNTHESIS AND CYCLIZATION OF MODIFIED PROSTATE-SPECIFIC ANTIGEN ACTIVATING 
PEPTIDES VIA SOLID-PHASE PEPTIDE SYNTHESIS METHOD 
 
 
 
 
 
 
JOEL EKABE (235142) 
SUPERVISOR: ALE NÄRVÄNEN 
CO-SUPERVISORS: MIIKKA PAKKALA & JANNE WEISELL 
DATE: 18-01-2012 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
Peptides have been used, in pharmaceutical research in diverse areas (neurology, 
endocrinology and haematology) due to their important role in many biologically relevant 
processes. For the therapeutic use, they can be modified chemically to increase their 
enzymatic stability, specificity, and bioavailability.  Prostate specific antigen (PSA) also 
known as kallikrein-related peptidase 3 (KLK3) is a potential target (biomarker) for cancer 
therapy due to its suggested antiangiogenetic properties. Discovering new lead molecules 
is one of the great challenges in drug research. Cyclic synthetic peptides B2 
(CVFAHNYDYLVC) and C4 (CVAYCIEHHCWTC) have been shown to increase the proteolytic 
activity of KLK3 and therefore, the development of newer modified B2 and C4 peptides for 
in vivo use is at high priority. B2 and C4 analogues (B2-W3 and C4_JE01-04) have been 
suggested to increase the proteolytic activity of KLK3, and previous research has shown 
that peptide prodrugs based on KLK3 substrates have therapeutic effect in vivo. The B2 
and C4 analogues were synthesized from Fmoc-Cys(Acm)-Wang resin using solid-phase 
peptide synthesis method with double coupling. The Kaiser or ninhydrin test was 
performed to confirm that complete coupling has occurred on all free amines on the resin. 
The completely synthesized peptide was cleaved from the resin and side chain protecting 
groups removed using a cleavage cocktail. The lyophilized peptides were cyclized using the 
iodination and/or iodination with subsequent ether precipitation method and the purity 
and molecular weight of the peptide was verified with analytical HPLC and mass 
spectrometry, respectively.  
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1. Introduction 
Prostate cancer or adenocarcinoma of the prostate (Pca) initiates in the prostate 
gland and becomes severe once it metastasizes to other parts of the body .i.e. bones and 
lymph nodes. Common symptoms are difficulty in urinating (dysuria), blood in the urine or 
semen (hematuria), problems during intercourse (erectile dysfunction), and may cause 
bone pain or tenderness e.t.c and some other symptoms that can augment during the 
later phase of the disease.1 Previous studies have shown that lowest level of prostate 
cancer is registered in Japanese men living in Japan, vegetarians and very high level in 
America (resulting in the death of ~25.000-29.900 American men annually).2,3-4 The 
development of the prostate cancer has been attributed to factors including genetics and 
diet. The presence of the prostate cancer may be indicated by symptoms, physical 
examination (rectal palpation), biopsy or, measuring the prostate specific antigen (PSA) 
levels in serum. PSA, commonly known as human tissue kallikrein 3 (KLK3) is a serine 
protease produced by prostate gland and its function is to keep the semen in its liquid 
form and allows sperm to swim freely.5PSA has also been suggested  to stimulate tumor 
growth6 by cleaving the insulin-like growth factor binding protein-3 (IGFBP) responsible for 
the release of active IGF-I, which stimulates cell growth.7 On the contrary Frontier et al has 
reported the anti-angiogenetic properties of KLK3, which may indicate tumor suppressing 
properties of KLK3.6 KLK3 is secreted in the lumen (figure 1.) as an inactive proenzyme 
(proPSA) and its concentration ranges from 0.5 – 2.0 mg/mL.8, 9 
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Figure 1.
10
PSA biosynthesis in a normal and cancer infected prostate epithelium cell. The prostate gland is 
surrounded by a consecutive layer of basal and basement membrane. proPSA produced by the secretory 
epithelium is deposited into the lumen where it is  cleaved by hK2 to produce active PSA. A fragment of the 
active PSA bound to protease inhibitor (ACT) in the serum and the other fraction is converted to inactive PSA 
via proteolysis and goes into the serum as free PSA. A characteristic feature of a Pca cell are losses of  large 
fragments of basal cells and disruption of basement membrane resulting to a decrease in production of 
proPSA and thus active PSA leading to an increase in bound PSA and proPSA in the serum.
11-12
   
 
ProPSA is a 28 kDa protein consisting of  244 amino acids and becomes activated 
and displays chymotrypsin-like enzymatic activity when 7 amino acids are cleaved by KLK2 
from the N-terminus.13 The significant physiological role of KLK3 is to cleave the gel-
forming proteins (seminogelin I and seminogelin II)  in the semen leading to liquefaction of 
semen impediments after ejaculation.14 KLK3 has also been identified in trace amounts in 
other tissues and biological fluids i.e. breast and saliva  but  its biological roles in these 
tissues is unclear.15  
In the serum a majority of KLK3 is  in the complex with α1-anti-chymotrypsin 
(ACT)/serpin A3, with minor amounts adhering to α2-macroglobulin or α1-
antitrypsin/serpin A1 and the remaining exists as unbound inactive enzyme (free PSA).16  
Only free PSA and PSA-ACT (total PSA) are detectable in immunoassays. During the 
development of Pca tumor PSA is released to the blood circulation and serum 
concentration of PSA is widely used in the diagnosis of the PCa. The accuracy of the test is 
interfered by benign prostate hyperplasia.   The ratio between free and total PSA are 
frequently found to be lower in prostate cancer than in benign hyperplasia.17 The 
expression of KLK3 is regulated by androgen due to the presence of androgen response 
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elements in its gene promoter.18 The presence of high levels of enzymatically active PSA 
only within the extracellular fluid of prostate cancer tumors suggests that a PSA inhibitor 
based method could be used for imaging and therapy for metastatic prostate cancer 
sites.19 On the contrary it has been shown that metastatic breast cancer with high levels of 
KLK3 has good prognosis and it has been suggested that further modulation of KLK3 
proteolytic activity may inhibit the growth of tumor.20 In a cancer infected prostatic 
epithelium cell, the expression of KLK3 is lower than in normal prostate tissue, and even 
more reduced in violent tumors indicating poor diagnosis. KLK3 has been suggested to 
exhibit both cancer promoting and cancer suppressing activities in the regulation of 
cancer growth even though this has not been extensively examined. Higher levels of KLK3 
in tumor tissue are linked with low microvessel density.54, 76-79    
Another important serine protease secreted by the prostate gland is KLK2 which 
exhibit 78% amino acid identity with KLK3 and has trypsin-like activity.21,22 KLK2 is tissue 
specific i.e. high levels have been detected only in prostate. KLK2 have been associated 
with increase of prostate cancer growth and metastasis hence, predict the presence of 
prostate cancer at biopsy.23-27 The roles of kallikreins are interconnected though the 
expression and regulation of different kallikreins in prostate cancer has not been 
compared.28 
1.1. The overall 3D structure of kallikrein-related peptidase 3 
 
The 3D structure of prostate kallikrein reveals that the S1 pocket of chymotrypsin-
like proteases consists of the catalytic triads His57, Ser195 and Asp102 (figure 2) located 
near the heart of the enzyme (active site) and function in catalysis. Ser195 binds to the 
substrate polypeptide to the side of surrounding residues i.e. phenylalanine, tryptophan, 
or tyrosine residues closer to the C-terminus, hence keeping it in place while the His57 
and Asp102 then hydrolyze the bond. 
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Figure 2.
29
 The overall 3D structure of prostate kallikrein isolated from stallion seminal plasma with five 
disulfide bridges (green) and the locations of the mercury and zinc atom-binding sites.  
The amino acid residue at the bottom of the S1 pocket exerts the chymotrypsin-like 
specificity for the P1 position and in most kallikrein the residue has been identified as 
negatively charged aspartic acid i.e. a variety of kallikrein exhibit trypsin-like specificity. In 
PSA the residue at the bottom is serine (Ser189) which is similar to that found in 
chymotrypsin as such they share some substrate specificity in common. Zn2+ and Hg2+ are 
potential inhibitors of PSA activity and binds to peptides having sequences matching Zn2+ 
binding sites on the zinc finger proteins. Zn2+ has been also shown to mediate high binding 
affinity between trypsin and its small molecule size inhibitor. Furthermore, Zn2+ is said to 
stabilize the 3-D structure of the peptides just like it interacts with the zinc finger 
proteins.30,31 
1.2. Development of KLK3-binding peptides using phage display 
 
Phage display method is a technique used to find zinc-finger proteins that will bind 
to a specific DNA target sequence using bacteriophages. The bacteria uses specifically the 
Gene 3 on the phage to produce a protein which assembles on one end of the phage 
hence, by inserting a variety of same zinc-finger protein into Gene 3 of the phage a library 
of phages each expressing a different zinc-finger protein can be produced.32-35 Phages 
modified from the original purpose has further used to characterized any linear and cyclic 
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peptide binding specifically to the target molecule. Phage display has been used to 
discover peptides that fine-tune the enzyme activity of proteases and such peptides are 
reported to stop tumor growth in vivo.34,36-37The synthetic cyclic peptides B-2 and C-4 
were identified using phage display peptide libraries  and have been reported to increase 
the serine protease activity of PSA.38,39These peptides with different amino acid sequence 
were identified to bind to the same region of active site making them potential lead 
compounds to target PSA. The prerequisites for binding was studied by alanine 
replacement.40 Recent development of phage display has led to the discovery of small-
molecule mimicking peptides i.e. biotin and sugar mimics. Streptavidin have a high affinity 
for biotin (a B-complex vitamin) and the non-covalent interaction between streptavidin 
and biotin is considered one of the strongest in nature. As a result of the resistance to 
organic solvents, denaturants the streptavidin-biotin complex is used in many applications 
e.g. molecular biology and bionanotechnology. Another protein avidin (cut off from egg 
white) share about 30% sequence identity with streptavidin also have very high affinity for 
biotin but not commonly used because it is easily glycosylated. The use of combinatorial 
methods like phage display strategies developed by Devlin et al.74  have provided flexible 
means to discover peptide-based biotin functional mimics.75 
 
1.3. Peptide modification strategies 
  There is often challenges’ to use peptides as drugs because they generally have 
poor in vivo stability, poor pharmacokinetics, and poor bioavailability, but this does not 
mean that they play no role in medicinal chemistry. They serve as highly important lead 
compounds for the design of novel drugs e.g. goserelin is a peptide drug used against 
breast and prostate cancers. 
1.4. Advantages and Disadvantages of peptides as drugs 
Peptides are versatile and have tremendous therapeutic properties due to their 
chemical and biological diversity. Furthermore, they exhibit high specificity, affinity and 
molecular recognition.  
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1.4.1. Disadvantages of peptides as drugs 
 
Some of the main disadvantages of peptides as drugs are described below:   
1. Undergo rapid degradation by peptidases in the gastrointestinal tract and in 
serum. 
2. Due to their relative high molecular weight and lack of specific transport systems, 
it is difficult to cross the plasma membrane or blood brain barrier. 
3. It undergoes rapid excretion via the liver or kidneys without reaching the target 
Excretion may be also beneficial, since excess of the drug should be neutralized. 
4. Result to undesired side effects due to interaction with multiple receptors besides 
the target attributed to its inherent flexibility. 
 
1.5. Peptidomimetics and pseudopeptides 
 
As a result of the shortcomings of peptides as potential drug candidates, it is necessary to 
structurally modify the peptides to improve their therapeutic efficacy and conformational 
stability. Peptidomimetics are structures, which improve the bioavailability of the 
polypeptides without losing its function. Peptidomimetics are designed using unnatural 
amino acids, dipeptides or  conformational restraints to mimic the bioactive conformation 
of the peptides and thus retain the ability to interact with the biological target with the 
same biological effect as original polypeptide.41 Peptidomimetic approaches are used for 
the design and synthesis of peptide analogues with improved pharmacological properties 
known as pseudopeptides or peptide bond surrogates by replacing one or more bonds 
with an isostere. Scheme 1. represents some examples of peptidic bond transformation to 
peptidomimetics containing the amide surrogates i.e. isosteric with the natural peptidic 
amide bond. 
Peptidomimetic structures   are used to optimize the specificity, oral bioavailability, 
decrease the side effects and increase the half-life through minimizing enzymatic 
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degradation and optimizing the potency and selectivity.42 Several methods have been 
developed in the discovery, development and optimization of pseudopeptides: 
1. Amide bond replacements - replacement of peptide bonds by non-peptide analogs 
e.g. carbamate, urea, hydrazines, lactams etc.  
2. Incorporation of non-peptide moieties – insertion of various bi-functional, non-
peptidic molecules within the peptide sequence. 
3. Peptide small molecule conjugates – small molecules attachment to side chains, 
and use of N-alkylated and non-natural amino acid derivatives 
4. Backbone cyclization – ring formation using proprietary building units, leads to 
cyclic peptides in which the amino acid side - chains are unaltered. 
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Scheme 1. Common amide bond isosteres. 
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1.5.1 Peptidomimetics in drug design 
 
A lead molecule is a chemical compound that has biological activity and whose 
chemical structure is used as a starting point for chemical modifications to enhance 
potency, selectivity or pharmacokinetic properties. The structure activity relationship 
studies (SARs) are the starting point for the modulation  of the peptide sequence with  
biological activity taking into consideration the binding affinities of the peptide derivatives 
to the target.41, 43-47  To improve the bioavailability i.e. enzyme stability, improved half life 
e.t.c.  conformational restrictions are used.41, 48 Cyclization is achieved by local and global 
constraints,43 N-methylation,49 isosteric replacement,50 or by secondary replacement.51 
 
1.6. Cyclic peptides and cyclization strategies 
 
Cyclic peptides are a class of compounds with improved biological activities and 
ranges from antibiotics to immunosuppressant drugs and toxins. They are much more 
resistant to enzyme degradation than non-cyclic peptide chain and are able to bind drug 
targets in vivo.  These cyclic peptides can be modified using several approaches e.g. N- and 
C-terminal capping, D-amino acids, side chain modifications, unusual amino acids, N-
alkylation of amide nitrogen and cyclization hence, enhance peptide stability.52    
Most natural peptides are linear and consist of a sequence of amino acids linked together 
by an amide bond. They have N-terminus with the amino group at one end and a C-
terminus with a carboxyl group at the other end. A cyclic polypeptide chain is formed by 
linking the N and C terminals together. Aside their biological activity, they act as carriers to 
convey drugs into the body e.g. Sophisen is a good carrier for Dichlofenac sodium by 
passive diffusion through the cornea.53  
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1.6.1. Peptide cyclization advantages and methods 
 
Cyclization can be used to mimic natural peptide structures or to synthesize more stable 
peptide structures, resulting in enhanced conformational stability when compared to their 
natural counterparts. A variety of peptide cyclization methods have been developed: 
1. Amide condensation (amide bond formation, lactam formation) 
2. Thiol oxidation (disulfide bridge formation) 
3. On resin cyclization 
4. Solution phase cyclization 
The two most commonly used methods of peptide cyclization will be described below. 
1.7. Amide condensation 
 
In this method an intramolecular amide bond is formed between an amino group 
(NH2) and a carboxyl group (COOH). There are four possibilities for amide condensation to 
take place:   
1. Between N-terminal to C-terminal 
2. Between N-terminal to internal COOH 
3. Between C-terminal to internal NH2 
4. Between NH2 to internal COOH 
 
1.7.1. Thiol oxidation (Disulfide bridge formation) 
 
In this method a disulfide bridge is formed between two thiol (SH) groups from the 
side chain of cysteine or cysteine analogues resulting to intermolecular (two peptide 
molecules are linked via the disulfide bridge forming homodimers or heterodimers) or 
intramolecular (cyclization within one peptide molecule) oxidation. Protecting groups are 
used to prevent undesired linkage. The disulfide bridge is formed between two cysteines, 
head-to-tail (i.e. backbone) cyclization between the N- and C-terminus, between side 
chains, between the terminus and side chain, or between unnatural amino acids or 
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synthetic building blocks. Head-to-tail cyclization has reduce the risk of peptide 
degradation i.e. enhanced the stability of peptides against proteases by eliminating the N- 
and C-termini.54  
1.8. Side-chain protecting groups 
 
 About 50 % of all amino acids encountered in SPPS have side-chains containing 
reactive functional groups. During peptide synthesis masking of these reactive groups is 
beneficial due to the severe conditions used to achieve the desired sequence and also to 
achieve the highest possible recovery of the product. Protecting groups that can be easily 
removed with TFA are usually used because they can be easily cleaved from the peptide or 
support during the deprotection phase. However, a variety of protecting groups can be 
used and thus will require different conditions for their removal (table 1). 
 
Side-chain functionality of AA Protecting groups Cleavage conditions 
Arg Mtr, Pmc, Pbf 90-95% v/v TFA, 4-6 
h TFA-anisole(9:1), 1 
h 
Asp/Glu OtBu  90% v/v TFA, 30 min 
 OAll Pd(Ph3P)4-AcOH-
NMM 
 ODmab 2% NH2NH2.H2O in 
DMF, 5-10 min 
Asn/Gln Trt 90% v/v TFA ,30-60 
min 
 Tmob 90% v/v TFA, 1h 
 Mtt 95% v/v TFA, 30 min 
Cys Acm  
 Trt 90% v/v TFA, 30 min 
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Side-chain functionality of AA Protecting groups Cleavage conditions 
 StBu  
 Tmob 5% TFA-3% TES in 
DCM 
 Mmt 0.5-1% TFA in DCM-
TES(95:5), 30 min 
His Trt 50% TFA in DCM, 30 
min 
 Boc 90% v/v TFA, 30 min 
Lys/Orn Boc 90% v/v TFA, 30 min 
 Alloc Pd(Ph3P)4(0.1 eq.)-
PhSiH3(24 eq.) in 
DCM, 10 min 
 Mtt 1% TFA in DCM, 30 
min AcOH-TFE-
DCM(1:2:7), 1 h 
   
Ser/Thr/Tyr tBu 90% v/v TFA, 30 min 
 Trt,  1-5% TFA in DCM, 2-
5 min 
Trp Boc i) 90% TFA, 1 h; 
ii) 1% aq. TFA, 1-2 h 
           Table 1.55 Common side-chain protecting groups used in Fmoc/tBu SPPS 
 
1.9. Cysteine protection 
 
 The presence of an atom of sulphur in cysteine and/or methionine makes them 
special amino acid residues in peptide chemistry. Handling of cysteine is challenging56-59 
because some targets requires Cys with its side-chain in the free thiol form, meanwhile an 
even number of Cys residues is required for other targets to ease the formation of 
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disulphide connection between each pair. The Cys protecting groups that are frequently 
used in Fmoc/tBu strategy are listed (table 2) together with the conditions in which they 
are stable and possible methods of removal. Different reaction conditions can yield the 
free thiol, thiolate metal salt (mercaptide), or disulphide. Peptides with four or more 
cysteine residues present a statistical obstacle, since they can, in principle give rise to 
three or more different intramolecular isomers. This obstacle has been addressed by using 
highly optimized conditions to produce a major regioisomer with the naturally occuring 
pairing.   
 
Lability Protecting group stability Removal condition 
Moderate acid Xan, Tmob, Mmt, Trt Base, Nucleophiles Dilute 
TFA/scavengers, I2, 
Tl(lll), Hg(ll), Ag(l), 
RSCl 
Concentrated acid Mob, Meb, tBu TFA, Base, RSCl, I2, 
Ag(l), HF(0°C) 
HF(0°C), Tl(lll), 
Ph(SO)Ph-CH3SiCl3, 
Hg(ll), NpsCl 
Metal ions Acm, Phacm HF(0°C), TFA, Base, 
HF 
Hg(ll), Ag(l), I2, Tl(lll), 
RSCl, Ph(SO)ph-
CH3SiCl3, penicillin 
amidohydrolase 
Reducing agents S-tBu, Pic TFA, HF (partial), 
Base, RSCl, HBr-
AcOH 
RSH, Bu3P, other 
reducing agents, 
Electrolytic 
reduction, Zn-AcOH 
Table 2.55 Cysteine protecting groups compatible with Fmoc/tBu SPPS 
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1.10. Overview of Preparative and Analytical HPLC 
 
In high-performance liquid chromatography, analyte molecules are injected into a 
column filled with particles capable of retaining them (stationary phase), and they are 
eluted out of the column with solvents (mobile phase) so that the least strongly retained 
analyte is eluted first into detector. Different additives are added to the mobile phase to 
optimize the separation and also for pH adjustment e.g., formic and acetic acids, trifluoro 
acetic acid (TFA), ammonium acetate, or phosphate buffers.60 HPLC is commonly used in a 
wide range of applications, including drug discovery and purification for the 
pharmaceutical and biotechnology industries, environmental analysis, forensics, 
petrochemical analysis, food, cosmetics and vitamins. Different columns are used with 
respect to the sample to be analyzed i.e. reversed-phase (for molecules that posses some 
degree of hydrophobic character e.g. peptides and can be separated with excellent 
recovery and resolution), normal-phase, hydrophilic interaction liquid chromatography 
(HILIC), ion-exchange, ion-exclusion, size-exclusion, and affinity stationary phases for 
small- and large-molecule separations. For proper performance of a HPLC column the 
following properties have to be taken into account i.e. particle shape, pore size and pore 
volume, particle size and particle size distribution, surface properties and metal 
impurities. For peptide separation C18 columns are recommended as the first choice 
because of their high capacity.  
Preparative chromatography is considered to a large extent to be a purification process 
using liquid chromatography. Preparative chromatography could be done in linear or non-
linear mode i.e. in the former the equilibrium concentrations of the component in the 
stationary and mobile phases are proportional and band shapes and retention times are 
independent of the amount of each component in the injected sample. The peak height is 
directly proportional to the amount and composition of the sample. In the latter i.e. non-
linear chromatography the concentration of a component in the stationary phase at 
equilibrium is not proportional to its concentration in the mobile phase as such the band 
shape, retention time and peak maximum depend on the amount and composition of the 
sample. In preparative chromatography larger amounts of sample are injected with the 
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main task to recover as much purified product as possible in each run. In analytical 
chromatography, smaller amounts of samples are often used (depending on the detection 
method) in order to identify and quantify the concentrations of the components in a 
mixture. The two chromatographic processes can be distinguished not by the size of 
sample or equipment but exclusively by the task of the separation process (table 3). 
Analytical HPLC Preparative HPLC 
Sample goes from detector into waste Samples goes from detector into fraction 
collector 
Main goal is for quantification and/or 
identification of compounds 
Main goal is for isolation and/or purification 
of compounds 
Sample can be processed, handled and 
modified to generate required information, 
including degradation, labeling or changing 
the nature of the compound under 
investigation 
The sample has to be recovered in exact 
condition before undergoing the separation 
i.e. no degrading elution conditions 
Table 3. Overview of the differences between analytical and preparative HPLC  
 
1.11. Mass spectrometry 
 
Mass spectrometry (MS) is an analytical tool used for measuring the mass-to-charge 
ratio (m/z) of charged particles. It is also used to determine the chemical structures of 
molecules e.g. peptides and other chemical compounds. Based on the ionization 
technique used, the mass spectrum may show a large number of peaks from fragment 
ions, that provide the structural data of the analyzed compound, or it may contain a peak 
solely for the molecular ion, providing information of the molecule or about the elemental 
composition of the molecule. An ionization source creates charged ions within the gas 
phase and a mass analyzer separates ions according to their mass to charge ratio value. 
The ions produced are as a result of loss or gain of one or more electrons, making them 
negatively or positively charged. The two primary methods for ionization of whole 
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proteins are Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization 
(MALDI).61 In a typical MS procedure: 
1. A sample is loaded onto the MS instrument and undergoes vaporization 
2. The components of the sample are ionized by one of a variety of methods ( e.g., by 
impacting them with an electron beam), which results in the formation of charged 
particles (ions) 
3. Directing the ions into an electric and/or magnetic field 
4. Computation of the mass-to-charge ratio of the particles based on the details of 
motion of the ions as they transit through electromagnetic fields, and 
5. Detection of the ions, by a quantitative method and the ion signal is processed into 
a mass spectra. 
A mass spectrometer consists of three basic components: 
1. An ion source, which can convert gas phase sample molecules into ions 
2. A mass analyzer, which sorts the ions by their masses by applying electromagnetic 
fields 
3. A detector, which measures the value of an indicator quantity and thus provides 
data for calculating the abundances of each ion present 
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2. Project tasks 
 
The use of peptides in pharmaceutical research is increasing due to the important 
role in many biological processes62 i.e. in the fields of neurology, hematology and 
endocrinology. Only few peptide drugs are available in the market for the treatment of 
disease because of their inherent enzymatic instability of unmodified peptides and their 
relatively poor bioavailability i.e. limits their potential as drug candidates. Contrary to 
their shortcomings, they are less toxic, more soluble but more complicated to synthesize 
than small organic molecules.63 Recent advances in genomics and proteomics, have led to 
the discovery of numerous protein and peptide drugs of therapeutic potential and a great 
number of peptides in various phases of clinical trials.64 About 720 peptide drugs and drug 
candidates were reported in 2004, of which 1% are registered, 5% are already in the 
market, 38% are in clinical trials and 56% in advanced preclinical phases.65 The discovery 
of a large number of naturally occurring peptides with potent and biological activities 
during the past 35 years has boosted their importance.66Peptide ligand act as agonists or 
antagonists at cell-surface receptors or acceptors that activate cell function and animal 
behavior e.g. learning, memory, response to stress, pain, addiction, sexual behavior and 
many others. The synthesis and development of peptide molecules that can target the 
receptors or acceptors that activate these biological processes is of high priority.67 
The B-2 peptide containing phenylalanine, tyrosine, valine (in second position) and the C-4 
peptides have been shown to bound specifically to KLK3, stimulate its proteolytic activity 
and is potential therapeutic peptide for PCa.68,40,54 
The main goal of this study was to synthesize modified PSA activating peptides B-2 and C-4 
(Table 4) using Fmoc-based solid-phase peptide synthesis (SPPS) method under standard 
conditions. B-2 (CVFAHNYDYLVC) is a peptide sequence consisting of 12 amino acids and 
undergoes structural modification by replacement from F3 to W3 to form the peptide 
sequence B2-W3 (CVWAHNYDYLVC). C-4 (CVAYCIEHHCWTC) is a 13 amino acid peptide 
containing cysteines at fixed positions (1, 5, 10 and 13) and undergoes substitution point 
mutations to form the analogues C4_JE01-C4_JE04 as shown below. Cyclization was 
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performed through disulfide bridging between two cysteins in the N- and C-terminals 
(Figure 3.).  
  
Peptide ID Peptide Sequence 
B2 CVFAHNYDYLVC 
C4 CVAYCIEHHCWTC 
B2-W3 CVWAHNYDYLVC 
C4_JE01 CVAYCIAHACWTC 
C4_JE02 CVAYCAEHACWTC 
C4_JE03 CVAYCAAHACWTC 
C4_JE04 CVAYCVEHHCWTC 
Table 4. Structurally modified B-2 and C-4 peptide analogues from B2 and C4. 
 
After cleavage from the solid support and purification by high-performance liquid 
chromatography (HPLC), their structures were confirmed by mass spectrometry and the 
purity was determined by analytical reversed-phase HPLC.  
 
CVFAHNYDYLVC
S S                                                                                  
CVAYCIEHHCWTC
S S
S S
 
Figure 3. The original B-2 (a) and C-4 (b) cyclic peptides with formation of Disulfide Bridge via two cysteins.  
The structures of the four modified peptides used in this study are shown below (figure 4). 
 
CVWAHNYDYLVC
S S        
CVAYCIAHACHWTC
S S
S S
      
CVAYCAEHACHWTC
S S
S S    
CVAYCAAHACHWTC
S S
SS  
Figure 4. Structures of successfully synthesized peptides 1-4 with corresponding ID B2-W3, C4_JE01, C4_JE02 
and C4_JE03 respectively. 
 
a) 
b) 
2 1 3 4 
24 
 
3. Results and discussion 
 
The first protocol for the synthesis of B-2 analogue, B2-W3 failed due to 
incomplete coupling of the amino acid residues as shown in the mass spectra. The second 
strategy was slightly modified from the first protocol to increase the coupling efficiency of 
the added amino acid. In the first protocol, a solution of activated Fmoc amino acid in 1 ml 
DMF was added to the resin and stirred for 40 min at RT for coupling and the second 
protocol, the activated Fmoc amino acid (1 ml) was divided into two (i.e. ½ ml solution in 
DMF) and added at intervals of 30 min with vigorous stirring for coupling to occur (double 
coupling).   B2-W3 and C-4 analogues were synthesized using the second strategy. The 
successfully synthesized peptides were cleaved from the resin and lyophilized under high 
vacuum. The yields of the crude peptide obtained are shown in table 5 below.  
Peptide ID Peptide Sequence Yields(crude peptide after lyophilization) 
(mg) 
B2-W3 CVWAHNYDYLVC 67.7 
C4_JE01 CVAYCIAHACWTC 25.2 
C4_JE02 CVAYCAEHACWTC 26.5 
C4_JE03 CVAYCAAHACWTC 21.9 
C4_JE04 CVAYCVEHHCWTC 2.9 
Table 5. Yields of crude peptide after cleavage from resin and lyophilization. 
 
The low yield of C4_JE04 was as a result of the resins broken into powder by the magnetic 
stirrer. As a result of this it was difficult for the peptide to filter through the PD-10 column 
easily. 
Detectibility of the peptides in UV detector depends on the different amino acid residues 
in the peptide sequence. Since our peptides consists of both non-aromatic and aromatic 
residues, the UV light detection was set at 220 nm and 280 nm, respectively which offer 
selective detection of the amino acid residues and amide bonds at these wavelengths. The 
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results of Kaiser Test of B2-W3 and C-4 analogue peptides are shown in Table 6 below. The 
Kaiser test was not performed after each deprotection due to the limited amount of resin.  
Table 6 - Results of Kaiser Test after the coupling of the respective amino acids as indicated with their 
respective subscripts (i.e. AA2 indicate after addition of amino acid residue 2).  
Kaiser test Resin  AA2a AA3a AA6a AA9a AA12a/AA13a 
1b n/a - - - - -/- 
2c + + + + + +/+ 
a
 After coupling of amino acid residue 2,3,6,9, 12 and 13 respectively. 
b
 Kaiser test before deprotection with 
20% piperidine to give a yellow colour (negative test). 
c
 Kaiser test after deprotection to give a dark blue 
colour (positive test).  
The first cyclization was unsuccessful for the C4 analogues as indicated by the mass 
spectra i.e. there was incomplete cyclization as such all the Acm protecting groups were 
still attached to the crude peptide hence no disulfide bond was formed. We made a 
recombination of all the fractions with similar masses for the four peptides and we 
obtained yields as shown in table 7 below. 
Peptide ID C4_JE01 C4_JE02 C4_JE03 C4_JE04 
Yield obtained 
(mg) 
3 5.1 5.9 0.5 
Table 7. Yield of C4 analogues with Acm protecting groups attached. 
Each of these peptides except C4_JE04 (cyclized using second method) was subjected to a 
second cyclization phase with same procedure as described above. The peptide recovery 
was very low (-0.1-0.7 mg) and the MS showed more of the oxidization products [M+32] 
and the potassium adduct [M+38] hence suppressing the signal intensity of the molecular 
ion [M+1]. The potassium ion could have been generated from the solvents or from the 
glassware used. The oxidation product is suggested to have emerged from the 
autoxidation of the diethyl ether used for washing the peptide after iodine cyclization. 
From the analytical HPLC these oxidation product seems difficult to isolate because it is 
merged with the peptide signal i.e. have same retention time as the peptide being 
analyzed.  
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We decided to continue with the second cyclization method with the remaining crude 
peptide (C4_JE01-C4_JE04) i.e. iodine cyclization with subsequent ether precipitation as 
described in the experimental section. After the cyclization process was completed, to the 
crude peptide solution was added into ice-cold ether and subsequent freezing and 
centrifugation afforded a light yellow or colourless crude peptide solid (> 7 mg except for 
C4_JE04). The peptides were purified by preparative HPLC, purity checked with analytical 
HPLC and finally characterized by mass spectrometry. However, in the case of C4_JE04 
instead of obtaining a precipitate of peptide, two solution layers were obtained consisting 
of an upper ether layer and a lower aqueous layer containing the peptide. The biphasic 
solution was cooled overnight in freezer after which the lower layer peptide solution froze 
allowing the upper ether layer to be decanted carefully. After thawing, the aqueous layer 
was then characterized as described above.  
Since the C4 point mutated peptides have four cysteines, there is a possibility of 
disulphide bond connection different from the structures in figure 10 above. i.e. pairing 
can occur between Cys 1-9 and Cys 4-13 and/or Cys 1-4 and Cys 9-13 (figure 5 ). The 
correct pattern can be determined using other experimental techniques e.g., mass 
spectrometry with respect to the fragments that will be observed from the mass spectra.  
                   
CVAYCIAHACHWTC
S S
S S
                                              
CVAYCIAHACHWTC
S S S S 
Figure 5. Other possible disulphide bond connection between the Cysteine residues. 
 
3.1. Purification of peptides 
 
The lyophilized crude peptide was analyzed with analytical HPLC to check the 
impurity profile and to determine if purification was required before iodine-cyclization. 
Both preparative and analytical HPLC were performed using XterraTM RP C18 5 µm 4.6 x 
250 mm column which afforded better separation than the previous column used for the 
first cyclization method i.e. Phenomenex Jupiter C18 RP 250 x 10.00 mm, 10 micron for 
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preparative and Xterra waters C18 240 x 1.4 mm column for analytical HPLC. The mass 
spectra indicated mass of peptide with the Acm protecting groups and we decided to go 
on with the cyclizaion process before purification. The retention time of the analyzed 
peptides were within the expected range for the B2 and C4 peptide analogues (9-17 
minute) with respect to the column used. The retention time varies due to slight 
differences in the peptide sequence and also due to external factors e.g., temperature, 
ratio/composition of solvent used, flow rate of mobile phase and the strength of analyte 
interaction with the stationary phase).  
The analytical HPLC chromatogram of B2-W3 (appendix 5) and C4_analogues (appendix 6-
8) with respect to their retention time and % purity are shown in table 8 below. The HPLC 
chromatogram of C4_JE01 (appendix 5) showed an extra peak at retention time 18,333 
originating from the background as observed from the blank run. The analytical 
chromatogram of C4_JE02 (appendix 6) showed three peaks close together thus, 
indicating the peptide is still impure and requires further purification since the purity is 
expected to be > 90% for the biological testing.  
3.2. Mass spectrometry of peptides 
 
The peptide recovery was higher than the previous method (0.5-2.5 mg) and the 
MS showed more of the potassium adduct [M+38] as the most abundant ion and some 
trace of the sodium adduct [M+23] hence, suppressing the signal intensity of the 
molecular ion [M+1] (table 6). The ionization was performed in the positive ion mode 
mass spectra from m/z 400-2000 with a time-of-flight MS instrument to determine the 
elemental composition of the peptides with high resolution and accuracy. The ions 
observed in the MS may be quasimolecular ions created by the addition of a proton (a 
hydrogen and denoted [M+H]+, or of another cation such as sodium ion, [M+Na]+, or the 
removal of a proton [M-H]-. Multiply-charged ions such as [M+nH]n+ (where n>1) are also 
often observed especially for large macromolecules. 
The mass spectrum (appendix 1) indicates a base peak at m/z 742.3683 assuming the 
peptide ions are most abundant in the 2+ charge state and molecular ion peak at m/z 
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1483.6731, which corresponds to the molecular mass of the protonated [M+H]+ form of 
the cyclic B2-W3 peptide i.e., [C68H90N16O18S2]
+.  
Table 8- Experimental data of B2-W3 and C-4 analogues 
Comp. ID Calculated 
molecular 
mass (g)
a 
Measured 
molecular 
mass (g) 
Observed 
ions (m/z) 
% purity Retention 
Time(tR),min (λ 
= 280 nm) 
Disulfide 
pairing 
B2-W3 1482.61 1483.7224 742.3269, > 90 10.200c Cys 1-12 
C4_JE01 1437.72 1438.4053  719.7604, 
738.7366, 
1476.4617, 
1460.2901 
> 90 9.583c Cys 1-13, 
Cys 4-9 
C4_JE02 1453.44 1454.3824 
 
738.7301, 
746.7157, 
1492.3209, 
1477.4341 
>50 14.975d Cys 1-13, 
Cys 4-9 
C4_JE03 1395.64 1396.3341 
 
717.7145, 
1418.4253, 
1433.4255, 
1417.4190 
> 90 15.458d Cys 1-13, 
Cys 4-9 
a
 Calculated using HighChem Mass Frontier software. 
b
 Mass of purified peptide obtained. 
c
 eluted using 
Jupiter C18 4.6x150mm column. 
d
 eluted using Xterra
TM
 RP C18 5 µm 4.6 x 250 mm column 
For the C4 analogue peptides with two disulfide bridges, the ions monitored were the 
protonated molecules [M+H]+, the alkali metal cation adducts i.e. the sodium adduct 
[M+Na]+ and potassium adduct [M+K]+. C4_JE01 (appendix 2) showed the expected 
molecular ion peak at m/z 1438.4983, a very intense base peak at m/z 738.7404 
corresponding to the 2+ charge adduct of potassium and a weak signal of m/z 1460.4642 
indicating the presence of sodium adduct. Secondly, C4_JE02 (appendix 3) we observed a 
weak precursor ion with m/z 1454.4526 and very intense 2+ charge adduct of potassium 
at m/z 746.7157 and a trace of 2+ charge at m/z 738.7301 corresponding adduct of 
sodium. Finally, for C4_JE03 (appendix 4) we observe the expected parent ion at m/z 
1396.4579, a very intense base peak at m/z 717.7187 corresponding to the potassium 
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adduct and a weak sodium adduct ion signal with m/z 1418.4253 respectively. The 
C4_JE04 did not show any expected ion thus, results are not reported in this study. The 
presence of the disulfide bridge(s) increases the structural stability and can also improve 
biological activity69-70 of these peptides.  
4. Conclusion and future aspects 
 
In this study we have successfully used solid-phase peptide synthesis method to 
synthesis and cyclized the B2 and C4 modified peptide B2-W3 and C4_JE01-C4_JE03 
respectively. Analytical reversed-phase HPLC was used for product isolation (purification) 
and mass spectrometry with ESI source in positive ion mode for peptide mass 
identification. ESI is considered a soft ionization technique because it typically produces 
only a few fragment ion and an intensive protonated molecule (deprotonated in negative 
ion mode), or in many cases adducts with alkali metal cations. The Na/K adducts observed 
are due to small amounts in the MS solvents, or MALDI matrix or even picked up from 
glass sample vials. The cation adducts are suggested to be suppressed using a basic HPLC 
buffer, an acidic ion exchange resin or performing the MS in the negative ion mode e.g., 
running C4_JE01 (calculated molecular mass, 1437) showed an intense parent ion at m/z 
1436.9340 and a weak signal at m/z 1472.9066 (M+36) which can be attributed to 
addition of two extra water molecules. The cation adducts were not observed in the 
negative ion mode. Furthermore, the presence of the cation adducts do not have any 
effect on the purity of the peptide as determined by the analytical chromatograms giving 
rise to very sharp single peak as expected. The retention time of the peptide varies with 
respect to the column used for the analysis. The C4_JE04 can be re-synthesized and taking 
into consideration the magnetic stirrer used for the synthesis so as not to break the resin 
into powder as previously observed. Both cyclization strategies proved efficient but the 
higher yield obtained from the ether precipitation method makes it to be more efficient 
over the normal iodine cyclization method. Depending on the in vitro biological assay 
evaluation result, we can draw conclusions whether the modified peptide binds 
specifically to KLK3 and increases its proteolytic activity as suggested. This will act as a 
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lead compound (starting point) for further development of peptidomimetic analogues of 
B2-W3 and C4 peptides to target prostate cancer. 
  In summary, we have shown that the double coupling SPPS and ether precipitation 
method are more efficient and reliable approach for the synthesis and cyclizaion of B2 and 
C4 analogue peptides with high purity. 
5. Experimental section 
5.1. General considerations 
 
All solvents and reagents were purchased from Sigma Aldrich and/or Fluka and all 
Fmoc amino acids/Wang resin from GLS Biochem and used without further purification. 
The reaction was performed in the empty PD-10 column. DMF was used for washing off 
impurities from other solvents and 20% piperidine in DMF was used as deprotection 
reagent i.e. removal of Fmoc Amino-Terminal protecting group. The “Kaiser Test’’ was 
used to confirm that each coupling step goes to completion and all the Fmoc protecting 
groups are removed. The “Kaiser Test’’ is a colorimetric test for the presence of amino 
groups and based on the reaction of ninhydrin with amino groups to form a dark blue 
adduct. The test consists of three test solutions: Ninhydrin (5% w/v) in ethanol (solution 
A), phenol (4:1 w/v) in ethanol (solution B) and potassium cyanide (2%, v/v, of a 1 
mmole/liter aqueous solution) in pyridine (solution C). The test is carried out by adding 
one drop of solutions A, B and C to the test sample in a small glass tube and then heating 
the tube for 2 minutes in a water batch (in beaker) at 100°C. The incomplete coupling 
develops a blue color of the resin (positive Kaiser Test) while coupling to completion will 
afford a yellow coloration (negative Kaiser Test). The Kaiser test is based on the color of 
the resin and not the colour of the solution because some amino acid residues can give 
unusual color change from red to blue e.g. Asn, Cys, Ser, Thr. HBTU and DIPEA were used 
as activation reagents (to activate the carboxylic acid by esterying it) prior to coupling. The 
peptide was cleaved from the resin with the cleavage cocktail made from a combination of 
trifluoroacetic acid, ethanedithiol, Tri-isopropylsilane and water. The cleavage cocktail 
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remove also the amino acid protecting groups. The peptide was precipitated and washed 
with diethyl ether and centrifuged using Hettich Zentrifugen Rotina 46 R.71 The lyophilized 
peptide was purified by HPLC (Shimadzu, Kioto, Japan) on a C18 reversed phase column 
(250 x 10.00 mm, 10 micron) (Phenomenex Jupiter) or XterraTM RP C18 5 µm 4.6x250 mm 
using an CH3CN gradient (0.1% TFA in H2O/0-90% CH3CN gradient for 60 min.). The purity 
were determined by analytical HPLC on a 240 x 1.4 mm C18 column (Xterra, Waters) 
and/or  XterraTM RP C18 5 µm 4.6x250 mm eluted with 0-90% CH3CN and fractions verified 
by mass spectrometry on an ABI QSTAR XL hybrid mass spectrometry using ESI interface 
(Applied Biosystems Inc., Foster City, CA, USA) for disulfide bridge formation. 
5.2. Peptide synthesis 
 
Peptides can be obtained by partial hydrolysis of proteins or by peptide synthesis. 
There are two methods for peptide syntheisis: 
1. Solution or liquid phase peptide synthesis (SPS) 
2. Solid phase peptide synthesis (SPPS) 
5.3.  Solution phase peptide synthesis 
 
Solution phase syntheis (SPS)  is a classical approach for  peptide synthesis and It is 
still useful in large-scale production of bioactive peptides in industry. However, it is time 
consuming, purification needed after each steps and coupling is less than 90% convention. 
I will not go into details of SPS since our target is to use SPPS to build our petides under 
investigation. 
5.4. Solid phase peptide synthesis 
 
Solid phase synthesis SPPS has replaced the SPS due to its high efficiency and 
purification, head-to-tail cyclization of peptide with minimal risk of intermolecular 
reactions i.e. dimerization and oligomerization even under high concentration.72   In SPPS 
amino acids are assembled on solid support  from the C-terminal to the N-terminal. The α-
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carboxyl group is attached via an acid-labile linker to a solid support, resin (figure 6). The 
resins are typically made from polystyrene. The amino terminal end of the amino acid is 
protected e.g. by a base-labile Fmoc or acid-labile Boc protecting groups while the side 
chains are protected to block the reactivity of that group (can be easily removed using 
mild reaction conditions) by acid-labile groups such as tBu. After the first amino acid is 
conjugated  onto the resin, the Fmoc group is removed using piperidine (deprotection). A 
Kaiser test is then performed to confirm that all of the Fmoc protecting groups are 
removed. The next Fmoc amino acid is then attached to the growing peptide by activation 
of its carboxyl group (coupling). A kaiser test is then performed to confirm that complete 
coupling has occurred on all free amines on the resin. Synthesis then proceed via a cycle of  
1. Deprotection of Fmoc amino terminus groups  
2. Coupling of the next amino acid until the peptide is completely synthesized. 
3. The completely synthesized peptide is cleaved from the resin and side chain 
protecting groups are removed using TFA (cleavage) or other cleavage cocktail 
depending on the types of protecting groups present. 
Load Resin e.g., Fmoc-Cys (Acm)-Wang resin
Coupling of first amino acid
Deprotection
Ninhydrin (Kaiser test)
Positive
Negative
WashCouple
Cleavage of synthesized peptide from resin
Purify and analyse
Kaiser test
Negative
Wash
Positive
 
                                            Figure 6. General scheme for SPPS. 
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5.4.1. General procedure for solid-phase Peptide synthesis 
 
Peptides were synthesized on Fmoc-Cys (Acm)-Wang resin (1 eq.) in a PD-10 
column. All couplings (double coupling method was used to ensure total coupling of the 
added amino acid) were performed in DMF and reagent solutions were added manually. 
Fmoc amino acids with the following protecting groups were used: acetamidomethyl 
(Acm) for Cysteins, tert-butyl (tBu) for tyrosine, tert-butyl ester (OtBu) for aspartic acids, 
tert-butoxycarbonyl (Boc) for tryptophan, trityl (Trt) for asparagine and histidine. Fmoc 
amino acids (4.9 eq.) were activated with HBTU (5 eq.) and DIPEA (10 eq.). All coupling 
reactions (after 30 min x 2 stirring at r.t.) were monitored using the Kaiser Test as 
described earlier for each amino acid. The Fmoc protecting group was removed by 20% 
piperidine in DMF (2 ml x 3) for 5 minutes intervals and washing with DMF (2 ml) for 5 
minutes after each deprotection step to ensure complete removal of piperidine with 
vigorous stirring. After final Fmoc deprotection, the resin was washed with DMF several 
times and dried under vacuum. Cleavage of the peptide from the resin and deprotection 
of acid labile protecting groups was accomplished by treatment with TFA/EDT/TIS/H2O 
(95:3:1:1, 2 ml) for 3 hrs. at room temperature (RT). The resin was filtered off and washed 
with acetic acid, and the filtrate (crude peptide) was precipitated into cold diethyl ether (-
20°C, 30 ml) for 20 minutes. The precipitate was centrifuged (8 min, 2800 rpm +4°C) and 
decants the ether away from the flask carefully.  The peptide pellet was washed with 7 ml 
of diethyl ether and centrifuged as described above and decant the ether away from the 
flask. The crude peptide was lyophilized from a mixture of water and 50% acetic acid.   
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6. Cyclization of the disulfide bridged peptide 
 
We have used two strategies to accomplish the cyclization of these B2-W3 and C4 
analogue peptides. i.e. iodine cyclization and the iodine/ether precipitation method. 
6.1. Iodine cyclization (B2-W3) 
 
The disulfide bond formation (cyclization) was formed via iodine oxidation 
method73 which is suitable for peptides with Acm protecting groups. This simultaneously 
removes the sulfhydryl protecting groups and disulfide bond formation between two 
cysteines. The lyophilized peptide (15 mg) was dissolved in H2O (0.75 ml), 100% AcOH 
(0.75 ml), 1M HCl (0.3 ml) and 0.1M I2 in 50% AcOH (1.8 ml). The above mixture was 
stirred vigorously at RT. under a N2 atmosphere for 2 hrs to avoid oxidation of the Cys 
residues. The reaction was stopped with addition of 1M Na2S2O3 dropwise until the 
solution becomes colourless i.e. solution changes from yellow to colourless. The peptide 
was filtered prior to analytical HPLC purification using a 0.45 µM filter and the formation 
of disulfide bond characterized with mass spectrometry after product isolation from 
different fractions using preparative HPLC as described above. The peptide was further 
repurified using the same column as described above since the purity for biological testing 
is expected to be > 90%. 
6.2. Simultaneous deprotection/oxidation of S-Acm with Iodine and 
subsequent ether precipitation (C4_JE01-C4_JE03) 
 
The crude peptide (10 mg) was dissolved in glacial acetic acid (10 ml) and to this 
solution were added 12.5 ml of 20 mM iodine/acetic acid and 5.0 ml of 60 mM HCl. The 
reaction mixture is purged by bubbling through N2, the tube is sealed and covered with 
aluminium foil, and stirring is carried out for 120 min at 25°C. The reaction was stopped by 
the addition of ice-cooled diethyl ether 50 ml (9 eq.). The resulting mixture was kept in the 
freezer overnight and then centrifuged (4100 rpm for 10 min, +4°C). The ether solution 
was carefully decanted and the yellow precipitate was washed with 10 ml of diethyl ether 
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and further centrifuged as above and the ether decanted from the flask. The crude 
peptide (yield > 7 mg) was lyophilized from a mixture of water and 50% acetic acid and the 
resulting yellow or colourless solid was purified using preparative HPLC and purity checked 
with analytical HPLC. The peptides were characterized by mass spectrometry.  
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APPENDIX 1: HPLC chromatogram of B2-W3. 
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Appendix 3: HPLC chromatogram of C4_JE02. 
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Appendix 5: Mass spectra of B2-W3.  
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Appendix 7: Mass spectra of C4_JE02.  
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